Professor Georgina Long AO
BSc PhD MBBS FRACP FAHMS AAHMS FAA FASCO
Medical Director & Medical Oncologist
Professor Georgina Long AO, BSc (Hons1, UM) PhD MBBS (Hons) FRACP FAHMS AAHMS FAA FASCO, is Medical Director of Melanoma Institute Australia (MIA), and Chair of Melanoma Medical Oncology and Translational Research at MIA and Royal North Shore Hospital, The University of Sydney. She leads an extensive clinical trials team and laboratory at MIA, with a focus on immuno-oncology and targeted therapies in melanoma. She is principal investigator on phase I, II and III clinical trials in (neo)adjuvant and metastatic melanoma, including trials in patients with active brain metastases. She is the chief investigator on NHMRC funded research into the molecular biology of melanoma, with a particular interest in clinical and tissue biomarker correlates of systemic therapy sensitivity and resistance.
In recognition of her ground-breaking research and work, Professor Long was named 2024 Australian of the Year and was awarded prestigious Fellowships with the American Society for Clinical Oncology (2025), the Australian Academy of Science (2024) and the Australian Academy of Health and Medical Sciences (2017), the latter awarding her the Outstanding Female Research Medal (2021). Professor Long was appointed as an Officer of the Order of Australia (2020) and has received numerous awards, including Fulbright U.S. Mission Australia Award for Leadership Excellence (2024), Estela Medrano Melanoma Award (2024), ESMO Women for Oncology Award (2023), Sydney Local Health District/Sydney Research 2022 Research Excellence Award (2022) the prestigious Ramaciotti Medal for Biomedical Research (2021), Vice Chancellor’s Award for Excellence Award for Outstanding Research (2021), University of Sydney (2021), Research Australia GSK Research Excellence Award (2018) and the Sir Zelman Cowen Universities Fund Prize for Discovery in Medical Research (2016). She has a number of CINSW Premiers Awards, including: the Outstanding Cancer Researcher (2018), the Excellence in Translational Cancer Research Award (2017), the Wildfire Award for the most highly-cited, original, peer-reviewed article published (2011, 2014, 2016, 2017, 2018, 2019 & 2020), and in 2013 she was named the Outstanding Cancer Research Fellow. She is a Clarivate highly-cited Researcher from 2017, with an H index of 155.
Professor Long is the author of over 610 peer-reviewed publications in clinical and translational research in melanoma, including the New England Journal of Medicine, Lancet, Lancet Oncology, Science, Nature, Nature Medicine, Journal of Clinical Oncology and Cancer Discovery. Professor Long has presented her work at international conferences and meetings on more than 300 occasions. She was President for the prestigious international Society for Melanoma Research (President 2018-2020), is a member and Chair of the ASCO (2015-2017) and ESMO (2017-2020 & 2026 – 2029) Scientific Committee for Melanoma/Skin cancer, is medical oncology lead for the Australian Melanoma Management Guidelines Committee, and is member of both the ASCO Plenary Series and ASCO AGM Education committees (2021-2024), Scientific Co-Chair for ESMO Asia (2024) and EADO (2026), she is on the editorial boards of several high-impact journals, and is a member of the Melanoma Expert Panel for AJCC Cancer Staging System 8th edition.
Professor Long was awarded the University Medal in Organic Chemistry. She subsequently completed her PhD in Chemistry in the field of anti-cancer agents and their binding to DNA. She then moved to the USA to take up a Fulbright Postdoctoral Fellowship at Scripps Research Institute, exploring nanotechnology in cancer treatment, before returning to Australia to complete her MBBS (Hons). Professor Long became a Fellow of the Australasian College of Physicians in January 2008, specialising in medical oncology.
Prof Long Recent News
Prof Long Recent Publications
Weber JS, Schadendorf D, Del Vecchio M, Larkin J, Atkinson V, Schenker M, Pigozzo J, Gogas H, Dalle S, Meyer N, Ascierto PA, Sandhu S, Eigentler T, Gutzmer R, Hassel JC, Robert C, Carlino MS, Di Giacomo AM, Butler MO, Muñoz-Couselo E, Brown MP, Rutkowski P, Haydon A, Grob JJ, Schachter J, Queirolo P, de la Cruz-Merino L, van der Westhuizen A, Menzies AM, Re S, Bas T, de Pril V, Braverman J, Tenney DJ, Tang H, Long GV. J Clin Oncol. 2022 Sep 26:JCO2200533. doi: 10.1200/JCO.22.00533. Epub ahead of print. PMID: 36162037.
Smith JL, Menzies AM, Cohen JV, Mut-Lloret M, Ozgun A, Spain L, Park J, Quach HT, Pallan L, McQuade J, Feng S, Sandhu S, Atkinson V, Tsai K, Long GV, Larkin J, Eroglu Z, Johnson DB, Sullivan R, Herkes GK, Henderson A, Carlino MS. Melanoma Res. 2022 Sep 23. doi: 10.1097/CMR.0000000000000825. Epub ahead of print. PMID: 36164923.
Müller-Jensen L, Zierold S, Versluis JM, Boehmerle W, Huehnchen P, Endres M, Mohr R, Compter A, Blank CU, Hagenacker T, Meier F, Reinhardt L, Gesierich A, Salzmann M, Hassel JC, Ugurel S, Zimmer L, Banks P, Spain L, Soon JA, Enokida T, Tahara M, Kähler KC, Seggewiss-Bernhardt R, Harvey C, Long GV, Schöberl F, von Baumgarten L, Hundsberger T, Schlaak M, French LE, Knauss S, Heinzerling LM. CEur J Cancer. 2022 Sep 22;175:224-235. doi: 10.1016/j.ejca.2022.08.009. Epub ahead of print. PMID: 36155116.
Lai-Kwon J, Kelly B, Lane S, Biviano R, Bartula I, Brennan F, Kivikoski I, Thompson J, Dhillon HM, Menzies A, Long GV. Support Care Cancer. 2022 Sep 22:1–10. doi: 10.1007/s00520-022-07360-4. Epub ahead of print. PMID: 36136246; PMCID: PMC9492451.
Newell F, Johansson PA, Wilmott JS, Nones K, Lakis V, Pritchard AL, Lo SN, Rawson RV, Kazakoff SH, Colebatch AJ, Koufariotis LT, Ferguson PM, Wood S, Leonard C, Law MH, Brooks KM, Broit N, Palmer JM, Couts KL, Vergara IA, Long GV, Barbour AP, Nieweg OE, Shivalingam B, Robinson WA, Stretch JR, Spillane AJ, Saw RPM, Shannon KF, Thompson JF, Mann GJ, Pearson JV, Scolyer RA, Waddell N, Hayward NK. Cancer Discov. 2022 Sep 13:CD-22-0603. doi: 10.1158/2159-8290.CD-22-0603. Epub ahead of print. PMID: 36098958.
Conway JW, Rawson RV, Lo S, Ahmed T, Vergara IA, Gide TN, Attrill GH, Carlino MS, Saw RPM, Thompson JF, Spillane AJ, Shannon KF, Shivalingam B, Menzies AM, Wilmott JS, Long GV, Scolyer RA, Pires da Silva I. J Immunother Cancer. 2022 Sep;10(9):e004884. doi: 10.1136/jitc-2022-004884. PMID: 36096531.
Eggermont AMM, Kicinski M, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, Haydon A, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Boers-Sonderen M, Di Giacomo AM, van den Eertwegh AJM, Grob J-J, Gutzner R, Jamal R, van Akkooi ACJ, Lorigan P, Grebennik D, Krepler C, Marreaud S, Suciu S, Robert C. NEJM Evidence. 2022 Sep 10. doi: 10.1056/EVIDoa2200214. Epub ahead of print.
Seviiri M, Scolyer RA, Bishop DT, Newton-Bishop JA, Iles MM, Lo SN, Stretch JR, Saw RPM, Nieweg OE, Shannon KF, Spillane AJ, Gordon SD, Olsen CM, Whiteman DC, Landi MT, Thompson JF, Long GV, MacGregor S, Law MH. J Transl Med. 2022 Sep 5;20(1):403. doi: 10.1186/s12967-022-03613-2. PMID: 36064556; PMCID: PMC9446843.
Bai X, Shoushtari AN, Betof Warner A, Si L, Tang B, Cui C, Yang X, Wei X, Quach HT, Cann CG, Zhang MZ, Pallan L, Harvey C, Kim MS, Kasumova G, Sharova T, Cohen JV, Lawrence DP, Freedman C, Fadden RM, Rubin KM, Frederick DT, Flaherty KT, Long GV, Menzies AM, Sullivan RJ, Boland GM, Johnson DB, Guo J. British Journal of Dermatology, n/a, no. n/a, (Mar 16 2022), doi:https://doi.org/10.1111/bjd.21241. TOP 10%
Simpson RC, Shanahan ER, Batten M, Reijers ILM, Read M, Silva IP, Versluis JM, Ribero R, Angelatos AS, Tan J, Adhikari C, Menzies AM, Saw RPM, Gonzalez M, Shannon KF, Spillane AJ, Velickovic R, Lazar AJ, Damania AV, Mishra AK, Chelvanambi M, Banerjee A, Ajami NJ, Wargo JA, Macia L, Holmes AJ, Wilmott JS, Blank CU, Scolyer RA, Long GV. Nat Med 2022 Sep 22. doi: 10.1038/s41591-022-01965-2. Epub ahead of print.
ZERO DEATHS FROM MELANOMA
Suzanne Sherwood says:
Steve Cole says:
Catherine Mardell says: